Istituto Romagnolo Per Lo Studio Dei Tumori Dino Amadori Irst S.r.l. Irccs
Clinical trials sponsored by Istituto Romagnolo Per Lo Studio Dei Tumori Dino Amadori Irst S.r.l. Irccs, explained in plain language.
-
App vs. paper: which diary boosts cancer pill adherence?
Knowledge-focused CompletedThis study tested whether a smartphone app helps cancer patients take their oral medications more consistently than a traditional paper diary. A total of 124 adults with solid tumors or blood cancers were randomly assigned to use either an electronic diary or a paper diary to tra…
Phase: NA • Sponsor: Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS • Aim: Knowledge-focused
Last updated May 17, 2026 03:23 UTC
-
Study reveals key factors for timely palliative care in advanced disease
Knowledge-focused CompletedThis study looked at 178 people with advanced cancer, chronic kidney disease, or serious lung conditions to find out when they need palliative care. Researchers used special scores to predict survival and guide care. No new treatments were tested; instead, the goal was to learn h…
Sponsor: Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS • Aim: Knowledge-focused
Last updated May 15, 2026 11:54 UTC
-
Italian study reviews Real-World use of targeted leukemia drug
Knowledge-focused CompletedThis study reviewed the medical records of 84 people with acute lymphoblastic leukemia (ALL) who received a drug called anti-CD22 outside of clinical trials in Italy. The goal was to better understand the drug's side effects, how well it works, and its costs in everyday practice.…
Sponsor: Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS • Aim: Knowledge-focused
Last updated May 13, 2026 16:01 UTC